tirzepatide for psoriasis with obesity: adding to ixekizumab improves complete clearance and weight loss Tirzepatide - DermOnDemand

Description

In a clinical trial up to 104 weeks of treatment, when administered with a sulfonylurea, hypoglycemia (glucose level 5%) of tirzepatide include: Nausea Vomiting Diarrhea Decreased Appetite Constipation Abdominal Pain Dyspepsia Adverse Reactions of tirzepatide include (mounjaro PI): Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)] Pancreatitis [see Warnings and Precautions (5.2)] Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)] Hypersensitivity [see Warnings and Precautions (5.4)] Acute Kidney Injury [see Warnings and Precautions (5.5)] Severe Gastrointestinal Disease [see Warnings and Precautions (5.6)] Diabetic Retinopathy Complications [see Warnings and Precautions (5.7)] Acute Gallbladder Disease [see Warnings and Precautions (5.8)] For more detailed information see above on this website under Contraindications & Precautions or see the Mounjaro PI Mounjaro PI: In monotherapy trials with tirzepatide injection for type 2 diabetes mellitus (T2DM), severe hypoglycemia (requiring the assistance of another person) was not reported in either the treatment group or the placebo group